Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 19/20 | 0.69 |
| ▸ | DHFR | P00374 | 2/20 | 0.67 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.67 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.67 |
| ▸ | GART | P22102 | 1/20 | 0.67 |
| ▸ | ATIC | P31939 | 1/20 | 0.67 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.67 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.67 |
| ▸ | FRK | P42685 | 1/20 | 0.67 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260030 | 0.99 | TYMS (0.67) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL7846955 | 0.93 | TYMS (0.66) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL18551642 | 0.91 | TYMS (0.64) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL13659935 | 0.89 | TYMS (0.63) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL2260032 | 0.88 | TYMS (0.68) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL25476851 | 0.87 | TYMS (0.64) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL14612488 | 0.87 | TYMS (0.67) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL13524779 | 0.87 | TYMS (0.67) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL8855177 | 0.87 | TYMS (0.61) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL22967337 | 0.86 | TYMS (0.59) | TYMSDHFRFOLR2FOLR1GART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539353-B | Pemetrexed polyglutamic acid metabolite and preparation method thereof | 南京碳硅人工智能生物医药技术研究院有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-112442038-B | Industrial preparation method of pemetrexed disodium | 德州德药制药有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-112174970-B | Method for preparing pemetrexed disodium with high yield | 德州德药制药有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-114539353-A | Pemetrexed polyglutamate metabolite and preparation method thereof | 南京碳硅人工智能生物医药技术研究院有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-110305134-B | Pemetrexed disodium intermediate and preparation method thereof | 鲁南制药集团股份有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-110305135-B | Pemetrexed disodium intermediate and preparation method thereof | 鲁南制药集团股份有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-112442038-A | Industrial preparation method of pemetrexed disodium | 德州德药制药有限公司 | 2021-03-05 | — | — | CN | claimed |
| CN-112174970-A | Method for preparing pemetrexed disodium in high yield | 德州德药制药有限公司 | 2021-01-05 | — | — | CN | claimed |
| EP-2882753-B1 | PROCESS FOR THE PREPARATION OF PEMETREXED AND LYSIN SALT THEREOF | BERLIN CHEMIE AG (DE) | 2016-10-05 | — | — | EP | claimed |
| EP-2882753-A1 | PROCESS FOR THE PREPARATION OF PEMETREXED AND LYSIN SALT THEREOF | BERLIN-CHEMIE AG (DE) | 2015-06-17 | — | — | EP | claimed |
| WO-2014024164-A1 | PROCESS FOR THE PREPARATION OF PEMETREXED AND LYSIN SALT THEREOF | BERLIN-CHEMIE AG (DE) | 2014-02-13 | — | — | WO | claimed |
| CN-102911176-A | Preparation method of pemetrexed disodium | DEZHOU DEYAO PHARMACEUTICAL CO LTD | 2013-02-06 | — | — | CN | claimed |
| WO-2012056285-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PEMETREXED | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-05-03 | — | — | WO | claimed |
| CN-1800169-B | Pemetrexed disodium key intermediate and its synthesis method, and method for synthesizing pemetrexed disodium from the said intermediate | SHANGHAI JINSE MEDICAL TECHNOLOGY DEV CO LTD | 2010-06-23 | — | — | CN | claimed |
| CN-1800169-A | Pemetrexed disodium key intermediate and its synthesis method, and method for synthesizing pemetrexed disodium from the said intermediate | SHANGHAI JINSE MEDICAL TECHNOL (CN) | 2006-07-12 | — | — | CN | claimed |
| CN-114539353-B | Pemetrexed polyglutamic acid metabolite and preparation method thereof | 南京碳硅人工智能生物医药技术研究院有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20230406859-A1 | METHOTREXATE ANALOGS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-21 | — | — | US | disclosed |
| US-5416211-A | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines | ELI LILLY AND COMPANY (US) | 1995-05-16 | — | — | US | disclosed |
| CN-1087910-A | The preparation method of pyrrolo-[2, the 3-d] pyrimidine that 5-replaces | LILLY CO ELI (US) | 1994-06-15 | — | — | CN | disclosed |
| EP-0589720-A2 | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines | ELI LILLY AND COMPANY (US) | 1994-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406859-A1 | METHOTREXATE ANALOGS AND METHODS OF USE | MTX1, MTX2, MGMT | TYMS 34/4885DHFR 9/4885FOLR2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.